Abromovitz, L., 60 Aitken, T.J., 97, 99

Baysinger, M., 78

Berman, S.J., 57

Betcher, D.L., 31, 87, 136, 192 Bowman, J., 50

Bryant, J., 3, 49

Burnbaum, N., 192

Burnham, N., 31, 87, 136

Clarke, D., 56 Clarke-Steffen, L., 52 Cohen, D.G., 68, 69 Connaughty, S., 56 Cook, K., 56

AUTHOR INDEX

Foley, G., 66

Foote, A., 17

Freiberger, D., 3 Gleason-Morgan, D., 139 Golden, D., 60

Gonzalez, L., 194 Guinan, E., 49

Hammer, E., 67

Hanigan, MJ., 71, 110 Heiney, S., 76

Heiney, S.P., 78

Hinds, P., 54

Hinds, P.S., 84

Hobbie, W., 55, 70 Hockenberry-Eaton, M., 132 Holcombe, J., 17

Patterson, K.L., 119 Pauckett, P., 54 Payne, K., 54 Perin, G., 57 Phipps, S., 54 Piazza, D., 17

Quargnenti, A.G., 84

Rasco, C., 33 Reid, D., 194

Sawin, K., 8 Servetar, E.M., 25

Hollen, P., 55 Sievers, T.D., 53 Dagesse, J., 50 Holt, C., 67 Smith, S., 69 Davies, B., 56 Hornberger, L., 60 Sonis, A, 70 DeZorzi, P., 63 Spector, R.E., 66 Donohoe, M.,, 54 Stewart, J.L., 159 Driscoll, J.W., 80 Keegan-Wells, D., 159 Stutzer, C., 56 Dulczak, S., 57 Klein, E.R., 170 Duncan, J., 76 Duncan, K., 50 LaVally, B., 60 Test, J., 60 Dunn, J., 79 Li, F.P., 64 Thompson, J.R., 67

Luciano, C.A., 48 Emery, J.E., 131 Wagner, D., 61 Mackenzie, B., 56 Walker, C.L., 29 Fairclough, D., 54 Marino, B., 3 Walsh, BA., 146 Feeg, V.D., 52 Martin, GA., 34 Walter, G.A., 110 Fergusson, J.H., 51 McCormick, J., 56 Weekes, D.P., 60, 187 Fish, L., 65 Wentz, T.J., 84 Fletcher, J.A., 64 O’Loane, M., 56 Williams, H.A., 77, 180 Fochtman, D., 1, 43, 145 Overbaugh, K.A., 8 Wright, P., 17 SUBJECT INDEX

Acetaminophen, 125, 127 Ancobon, 150 Addiction, pain medication and, 126-127 Anthropometric mesurement, 113-114 Adolescent Antibiotic, 150

decision making and risk taking characteristics of, 55-56 education intervention program for, 78-79 patient-controlled analgesia for, 68 self-esteem and, 8-16 support group for, 76 symptom distress in, 84-86

Amikacin, 150

Amikin, 150

Aminoglycoside, 150

Amphotericin B, 150, 194-195

Analgesia, patient-controlled, 68

Antidepressant, 126 Antiemetic, 103-104 Antifungal agent, 150 Antihistamine, as antiemetic, 103-104 Antiseptic, central venous line dressing change and, 3-7 Anxiety, music therapy and, 33-34 APON, See Association of Pediatric Oncology Nurses Aspirin, 127 Association of Pediatric Oncology Nurses Annual Confer- ence, 1991, 46-80 bone marrow transplantation overview, 49

Journal of Pediatric Oncology Nursing, Vol 9, No 4 (October), 1992: pp 199-202 199

| |

200 Indexes

Annual Conference (Continued)

cancer family syndrome, 64

case study model for pediatric oncology nursing course, 61-62

chemotherapy certification program, 63

chemotherapy update, 65

chromosomal abnormalities, 64-65

classroom teacher with students undergoing cancer treat- ment, 60-61

conscious sedation with midazolam, 53-54

cultural responses to illness, 66-67

developmental outcomes of childhood cancer, 52

educational trajectory approach, 78-79

family transition in childhood cancer, 52-53

grief workshop for pediatric oncology nurses, 54-55

historical perspective of pediatric oncology nursing, 51

home movies for school re-entry, 69

long-term endocrine effects of cancer therapy, 70

New England Medical Center Floating Hospital for Infants and Children, 50-51

nurse manager strategies, 48

nursing care to terminally ill children, 56-57

Nursing Research Committee, 57-59

open communication about end-stage disease, 57

oral complications of cancer treatment, 70

patient-controlled analgesia, 68

pediatric brain tumor, 60, 67-68

peer review tool, 79

risk taking and decision making in adolescent cancer sur- vivors, 55-56

self-care for nurses, 80

social support for black parents versus white parents, 77- 78

support groups, 76

unrelated bone marrow transplartation, 71-75

writing for publication, 66

Bactrim, 150

Barbiturate, 123

Bed, 156

Benzodiazepine, 104, 123

Betadine, for central venous line dressing change, infection

and, 3-7

Bone marrow transplantation, 49 unrelated, 71-75

Brain tumor effects on cognition and learning, 67-68 nursing challenges in, 60

Breathing exercise, 124

Broviac catheter, 159

Camptothecin, semisynthetic analog of, 31-32 Candida, 147, 148, 150, 153 Case study model, for pediatric oncology nursing course, 61-62 Catheter, See also Venous access device(s) Broviac, 159 central peripherally inserted, 161, 163-164 tunneled, 160-162

Catheter (Continued) infection related to, dressing change and, 3-7 Twiddler’s syndrome and, 25-28 2-CDA, See Chlorodeoxyadenosine Ceftazidime, 150 Central venous catheter, complications of, 81-83 Cephalosporin, 150 Certification program, 61-63 Chemotherapy certification program for administration of, 61-63 extravasation in, 65 handling of agents for, 65 Chloral hydrate, 123 Chlorhexidine, See also Hibiclens in stomatitis, 100 2-Chlorodeoxyadenosine (2-CDA), 192-193 Choline magnesium trisalicylate, 127 Chromosome abnormality, cancer and, 64-65 Clavulanic acid, 150 Cognition, brain tumor and, 67-68 Colony-stimulating factor, 152 Communication, end-stage disease and, 57 Constipation, cancer therapy and, 105-106 Corticosteroid, 104, 126-127 Cultural factor, in response to illness, 66-67

Decision making, adolescent cancer survivor and, 55-56

DEN, See Food and Drug Administration, Device Experi- ence Network

Development, in Neuman Systems Model, 21-22

Dexamethasone, 104

Diarrhea, 106-107

Diazepam, 123

Diflucan, 150

Distraction, during medical procedure, 124

Dressing change, catheter-related infection and, 3-7

Education adolescent undergoing cancer treatment and, 78-79 intervention for teacher and, 60-61 End-stage disease, nursing experiences and, 56-57 Endocrine system, cancer therapy effect on, 70 Environment, Neuman Systems Model and, 19, 21

Family human immunodeficiency virus handbook for, 139-140 risk of cancer in, 64-65 support for, 180-186 FDA, See Food and Drug Administration Fentanyl, 123 Fiber, dietary, 105 Fluconazole, 150 Flucytosine, 150 Fludara, 87-89 Fludarabine phosphate, 87-89 Fluid and electrolyte balance, cancer therapy and, 102-105 Fluof cytosine, 150 Food and Drug Administration Central Venous Catheter Working Group, 81-83 Device Experience Network, 82-83

1

Fortaz, 150

Fungal infection, 150, See also Candida

Fungizone, 150

Future expectations, of adolescent survivor of childhood cancer, 8-16

Gastrointestinal disorder, cancer therapy and, 99-109

Gauze, in central venous line dressing change, infection and, 3-7

Genetics, cancer and, 64-65

Gluconeogenesis, 111

Graft-versus-host disease, diarrhea and, 107

Grief workshop, for pediatric oncology nurse, 54-55

Halothane, 123 Hibiclens, See also Chlorhexidine in central venous line dressing change, infection and, 3-7

Histiocytosis, Langerhans’ cell, Twiddler's syndrome and, 25-28

Home movie, for school re-entry, 69

Human immunodeficiency virus, family handbook for, 139- 140

Hycamptamine, 31-32

Hypnosis, 124

Hypoproteinemia, 111

Ibuprofen, 127

Imagery, 124

Imidizole, 150

Infection acute lymphocytic leukemia and, 146-158 central venous line dressing change and, 3-7 fungal, 150, See also Candida

Invasive procedure pain and, 53-54, 122-125, See also Pain premedication for, 170-179

Ketamine, 123 Ketoconazole, 150

Langerhans’ cell histiocytosis, Twiddler’s syndrome and, 25- 28 Learning, brain tumor and, 67-68 Leukemia lymphocytic, acute, 146-158 Neuman Systems Model in nursing care for, 17-24 Lidocaine, 123 Lorazepam, 104, 123 Lumbar puncture, music therapy during, 33-34

Malnutrition, 110-118 Marijuana, 104 Mattress, 156 Media Review, 35-38, 90-93, 141-144, 196-198 Mentorship, 132-135 Meperidine, 123 Metoclopramide, 104 Midazolam, 53-54, 123 for outpatient sedation, 136-138 Morphine sulfate, 123 Motrin, 127

Mouthwash, 101

Multidisciplinary health care delivery system, 50-51 Music therapy, during lumbar puncture, 33-34 Mycostatin, in stomatitis, 100

Naprosyn, 127 Naproxen, 127 Nausea, cancer therapy and, 102-105 Neuman Systems Model catheter related infection and, 4-5 overview of, 17-24 Neutropenia febrile, 149 stomatitis and, 99 New England Medical Center Floating Hospital for Infants and Children, 50-51 Nitrous oxide, 123 Nizoral, 150 Nonsteroidal anti-inflammatory drug, 125 Nurse manager, 48 Nursing diagnosis, in Neuman Systems Model, 22-24 Nursing Research Committee, 57-59 Nutrition, 110-118 Nystatin, 150

Opioid, 123, 125-126, 127 Oral complications, of cancer treatment, 70 Oral hygiene, 101

p53 tumor suppressor gene, 64 Pain, 119-130 addiction considerations in treatment for, 126-127 assessment of, 119 behavior scales for, 120, 121 disease-related, 125-129 epidemiology of, 119 midazolam for, 53-54 pharmacological management of, 123 physiological manifestations of, 120 self-report measures for, 120, 121 treatment of, 120-122 treatment-related, 53-54, 122-125 Parent of adolescent survivor of childhood cancer, 8-16 black, support for, 77-78 health professional as, 184-185 support group for, 76-78 Peer review tool, 79 Penthothiazine, 103 Pentobarbital, 123 Pneumocystis carinii, 146 Procainamide derivative, 104 Prostaglandin, 104 Protein, metabolism of, 111 Providone-iodine, in central venous line dressing change, infection and, 3-7 Psychological factor, in Neuman Systems Model, 21 Psychology, nutrition and, 112 Psychosocial responses, of family, 52-53 Psychostimulant, 126 Publication, writing for, 66

Indexes 201 ‘

202 Indexes

Relaxation training, 124 Research, 132-135 human response in, 189-190 patterns and trends in, 188 personal experience as source of, 187-188 problem identification in, 187-191 theoretical frameworks for, 188 Rifampin, 150 Risk taking, adolescent cancer survivor and, 55-56

Salicylate, 125 School home movies for re-entry to, 69 intervention in, 78-79 student undergoing cancer treatment and, 60-61 Self-esteem, adolescent survivor of childhood cancer and, 8-16 Self-talk, positive, 124 Sepsis, catheter-related, dressing change and, 3-7 Serotonin antagonists, 104 SK&F 104864, See Topotecan Skin care, 151, 155-157 catheter-related infection and, 4 Social support for black parents, 77-78 for family, 180-186 Staff, support group for, 76 Steroid, 104 Stomatitis, cancer therapy and, 99-102 Stress, pediatric oncology nurse and, 54-55 Student, effect of cancer treatment on, 60-61 Sulfonanide, 150 Support group for adolescent, 76 for parent, 76-78

Supportive care, nursing, 97-98 Survivor, adolescent, self-esteem and, 8-16 Symptom distress, in adolescent, 84-86

Teacher, with students undergoing cancer treatment, 60-61

Tegaderm, in central venous line dressing change, infection and, 3-7

Terminal illness, nursing experiences with, 56-57

Ticarcillin, 150

Timentin, 150

Tolerance, drug, 126

Topotecan, 31-32

Trilsate, 127

Twiddler's syndrome, case report of, 25-28

Ulcer, skin, 155-157

Vancocin, 150

Vancomycin, 150

Venous access device(s), 159-169, See also Catheter comparison of, 161 complications associated with, 164-167 developmental considerations for, 167 history of, 159 implanted infusion port as, 161, 162-163 patient and parent education for, 167-168 peripherally inserted central catheter as, 161, 163-164 tunneled central catheter as, 160-162 types of, 160-164

Vomiting, cancer therapy and, 102-105

WHO, See World Health Organization

World Health Organization, ladder approach to pain, 125 Wound care, 155-157

Writing, for publication, 66

\

a